Dietary polyamine intake and risk of colorectal adenomatous polyps

American Journal of Clinical Nutrition

Volumn 96, Issue 1, 2012, Pages 133-141

  Vargas, Ashley J ^a   Wertheim, Betsy C ^c   Gerner, Eugene W ^b,c   Thomson, Cynthia A ^a,c   Rock, Cheryl L ^d   Thompson, Patricia A ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORNITHINE DECARBOXYLASE; POLYAMINE; URSODEOXYCHOLIC ACID;

ARIZONA FOOD FREQUENCY QUESTIONNAIRE; ARTICLE; COLORECTAL ADENOMA; CONTROLLED STUDY; DIETARY INTAKE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; WHEAT BRAN;

ADENOMATOUS POLYPS; AGE FACTORS; COLORECTAL NEOPLASMS; DIET; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; NUTRIGENOMICS; ORNITHINE DECARBOXYLASE; POLYAMINES; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES; RISK FACTORS; SEX CHARACTERISTICS;

TRITICUM AESTIVUM;

EID: 84863567780     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.030353     Document Type: Article

References (37)

1. Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem 2006;139:27-33. (Pubitemid 43258843)
2. Carper SW, Tome ME, Fuller DJ, Chen JR, Harari PM, Gerner EW. Polyamine catabolism in rodent and human cells in culture. Biochem J 1991;280:289-94.
3. Gerner EW. Cancer chemoprevention locks onto a new polyamine metabolic target. Cancer Prev Res (Phila) 2010;3:125-7.
4. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92. (Pubitemid 39331150)
5. Gerner EW, Meyskens FL Jr. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 2009;15:758-61.
6. Gerner EW, Meyskens FL Jr, Goldschmid S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids 2007;33:189-95. (Pubitemid 47222961)
7. Milovic V. Polyamines in the gut lumen: bioavailability and biodistribution. Eur J Gastroenterol Hepatol 2001;13:1021-5. (Pubitemid 32905192)
8. Uemura T, Gerner EW. Polyamine transport systems in mammalian cells and tissues. Methods Mol Biol 2011;720:339-48.
9. Uemura T, Stringer DE, Blohm-Mangone KA, Gerner EW. Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2010;299:G517-22.
10. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003;376:1-14. (Pubitemid 37487199)
11. Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner EW, Meyskens FL Jr. Development of a polyamine database for assessing dietary intake. J Am Diet Assoc 2007;107:1024-7. (Pubitemid 46764596)
12. Tome ME, Gerner EW. Cellular eukaryotic initiation factor 5A content as a mediator of polyamine effects on growth and apoptosis. Biol Signals 1997;6:150-6. (Pubitemid 27380006)
13. Wallace HM. The polyamines: past, present and future. Essays Biochem 2009;46:1-9.
14. Shantz LM, Pegg AE. Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. Int J Biochem Cell Biol 1999;31:107-22. (Pubitemid 29094793)
15. Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, Gerner EW. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 1993;2:369-74.
16. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res 2008;14:2303-9. (Pubitemid 351551061)
17. Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst 2010;102:1513-6.
18. Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, Neuhausen SL, Gerner EW, Anton-Culver H. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 2009;15:6208-16.
19. Ignatenko NA, Besselsen DG, Roy UK, Stringer DE, Blohm-Mangone KA, Padilla-Torres JL, Guillen RJ, Gerner EW. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis. Nutr Cancer 2006;56:172-81. (Pubitemid 46417677)
20. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, Reid ME, Ritenbaugh C, Vargas PA, Bhattacharyya AB, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-62. (Pubitemid 30211046)
21. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97:846-53. (Pubitemid 40909127)
22. Martínez ME, Marshall JR, Graver E, Whitacre RC, Woolf K, Ritenbaugh C, Alberts DS. Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol Biomarkers Prev 1999;8:941-6. (Pubitemid 29508732)
23. Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW, Kealey S, Jones VE, Caan BJ, Gold EB, et al. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials 2002;23:728-56. (Pubitemid 36005481)
24. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-69. (Pubitemid 16047362)
25. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 2003;100:7859-64. (Pubitemid 36760060)
26. Raj KP, Zell JA, Rock CL, McLAren CE, Zoumas-Morse C, Gerner EW, Meyskens FL. Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas: A potential target for colon cancer chemoprevention. ASCO: Gastroentestinal Cancers Symposium 2010 (abstr 279).
27. Lee JE, Willett WC, Fuchs CS, Smith-Warner SA, Wu K, Ma J, Giovannucci E. Folate intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin Nutr 2011;93:817-25.
28. Martínez ME, Giovannucci E, Jiang R, Henning SM, Jacobs ET, Thompson P, Smith-Warner SA, Alberts DS. Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. Int J Cancer 2006;119:1440-6. (Pubitemid 44258823)
29. Martínez ME, Thompson P, Jacobs ET, Giovannucci E, Jiang R, Klimecki W, Alberts DS. Dietary factors and biomarkers involved in the methylenetetrahydrofolate reductase genotype-colorectal adenoma pathway. Gastroenterology 2006;131:1706-16. (Pubitemid 44958511)
30. Zell JA, Ignatenko NA, Yerushalmi HF, Ziogas A, Besselsen DG, Gerner EW, Anton-Culver H. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer 2007;120:459-68. (Pubitemid 44969014)
31. de Vogel S, Dindore V, van Engeland M, Goldbohm RA, van den Brandt PA, Weijenberg MP. Dietary folate, methionine, riboflavin, and vitamin B-6 and risk of sporadic colorectal cancer. J Nutr 2008;138:2372-8.
32. Kolligs FT, Crispin A, Munte A, Wagner A, Mansmann U, Goke B. Risk of advanced colorectal neoplasia according to age and sex. PLoS ONE 2011;6:e20076.
33. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006;355:1863-72. (Pubitemid 44664644)
34. Barry EL, Baron JA, Bhat S, Grau MV, Burke CA, Sandler RS, Ahnen DJ, Haile RW, O'Brien TG. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst 2006;98:1494-500. (Pubitemid 44605594)
35. Zell JA, Mclaren CE, Gerner EW, Meyskens FL. Ornithine decarboxylase (Odc)-1 gene polymorphism effects on baseline tissue polyamine levels and adenoma recurrence in a randomized phase III adenoma prevention trial of DFMO + sulindac versus placebo. ASCO: Annual Meeting 2008 (abstr 1502).
36. Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90:1212-8. (Pubitemid 28407087)
37. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008;1:32-8.